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Abstract: Malignant pleural mesothelioma is a resistant form of lung cancer, and its incidence 
continues to rise in Europe and Australia. Until recently, chemotherapy had not been shown 
to be effective in the treatment of this slowly progressive disease. In 2004, the combination of 
pemetrexed and cisplatin was shown to induce high response rates in MPM. This article reviews 
the published literature describing the development and testing of this therapeutic combination 
in mesothelioma, and examines in detail the key phase III clinical trial that led to the approval 
of pemetrexed by the US FDA. Ongoing research will further deﬁ  ne the role of pemetrexed 
plus cisplatin in the treatment of MPM.
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Methodology
A systematic review of the literature was performed for published articles describing 
the development and testing of the combination of pemetrexed and cisplatin in the 
treatment of malignant pleural mesothelioma. Selected references and conference 
abstracts were also reviewed.
Introduction
Epidemiology
Malignant pleural mesothelioma (MPM) is a slowly progressive tumor involving the 
lining of the lungs; approximately 80% of cases are linked to prior asbestos exposure 
(Robinson et al 2005). In the US, approximately 2500 new cases of mesothelioma are 
diagnosed each year (Weill et al 2004). Asbestos use was banned in the US in 1971, 
and so the incidence of mesothelioma in the US is expected to continue to steadily 
decline.(Hazarika et al 2005) In contrast, asbestos use continued in Australia until 
2003 and in Europe until 2005. As a result, the incidence of mesothelioma in European 
countries continues to rise and is projected to peak in 2020, and may account for as 
many as 250,000 European deaths in the next 35 years (Gatzemeier 2004). In 2020, 
over 18,000 Australian cases will be diagnosed (Hazarika et al 2005). Over the next 
40 years, the direct and indirect costs of mesothelioma care will total over $200 billion 
in the US alone, making MPM therapy an important public health issue (Robinson 
and Lake 2005).
Prognosis
MPM carries an extremely poor prognosis, and the median survival of patients with 
MPM is often as little as 7 months (Budde and Hanna 2004). Due to the insidious and 
progressive nature of this cancer, only 10%–15% of patients have resectable disease Therapeutics and Clinical Risk Management 2008:4(1) 206
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at presentation (Budde and Hanna 2004). In addition, the 
lengthy delay between asbestos exposure and the develop-
ment of MPM mean that patients are often older and have 
signiﬁ  cant comorbidities that render them poor surgical 
candidates at the time of diagnosis. As a result, chemothera-
peutics have become the mainstay of disease therapy.
Cisplatin and standard 
chemotherapy
As recently as 2003, single-agent chemotherapy regimens 
produced response rates below 20% in MPM (Pistolesi and 
Rusthoven 2004), and single agents had not been shown to 
improve median survival. Given the poor response of MPM 
to traditional chemotherapy regimens, the British Thoracic 
Society only recommended chemotherapy within the con-
text of clinical trials as recently as 2001 (British Thoracic 
Society 2001).
Cisplatin has long been a mainstay in the treatment of 
lung cancer, including MPM. Zidar et al reported a 14.3% 
response rate to single-agent cisplatin (Zidar et al 1988). In 
a subsequent meta-analysis, Berghmans et al (2002) reported 
response rates of 22.6% with combination chemotherapy, sig-
niﬁ  cantly higher than the 11.6% response from single-agent 
regimens (p   0.001). Cisplatin was the most active single 
agent reviewed, with a response rate of 23%. The combina-
tion of cisplatin and doxorubicin was the most active doublet, 
with a response rate of 28.5%. Almost all of these trials 
enrolled fewer than 50 patients, calling the reproducibility 
of these results into question. While median survival is the 
most clinically relevant endpoint of chemotherapy testing, 
the bulk of pemetrexed trials prior to 2003 were phase I or II 
studies, forcing Berghmans et al to use response rate as the 
key endpoint in their meta-analysis (Berghmans et al 2002; 
Budde and Hanna 2004) .
Pemetrexed
Mechanism of action
Proliferating tumor cells depend on de novo nucleotide 
synthesis for their survival, and antimetabolite compounds 
such as pemetrexed are designed to inhibit nucleotide pro-
duction (Curtin and Hughes 2001). This effect is reversible; 
preclinical testing showed that exogenous hypoxanthine and 
thymidine were necessary to prevent growth inhibition by 
pemetrexed (Curtin and Hughes 2001).
Lower levels of pemetrexed (Eli Lilly and Company, 
Indianapolis, IN, USA) inhibit thymidylate synthase 
and dihydrofolate reductase, while higher levels inhibit 
glycinamide ribonucleotide formyltransferase, inhibiting 
purine synthesis (Hazarika et al 2005). In human leukemia 
cells, treatment with pemetrexed resulted in lower concentra-
tions of dTTP, dGTP and dCTP (Curtin and Hughes 2001).
Pemetrexed monoglutamate is transported into cells by 
the reduced folate carrier, and is subsequently polyglutamated 
by the folylpolygamma-glutamate synthetase (Hazarika et al 
2005). The addition of multiple glutamate moieties enables 
the compound to be retained in the cell for longer periods, 
and increases the compound’s afﬁ  nity for cellular enzymes 
needed for the de novo synthesis of adenosine, guanine and 
thymidine (Hazarika et al 2005). For example, the penta-
glutamatation of pemetrexed increases its ability to inhibit 
thymidylate synthase 84-fold (Curtin and Hughes 2001).
Pharmacokinetics
Pemetrexed is renally excreted, with a half-life of 3.5 hours 
(Hazarika et al 2005). After intravenous pemetrexed infusion, 
90% of the original dose is excreted unmetabolized in the 
urine within 24 hours (Hazarika et al 2004). Pemetrexed has 
not been tested in patients with creatinine clearance under 
45 mL/minute, and so should not be used in these patients 
(Hazarika et al 2005). Nonsteroidal anti-inﬂ  ammatory drug 
(NSAID) use may decrease renal clearance of pemetrexed, 
and should be avoided around the time of pemetrexed admin-
istration (Hughes et al 2002).
Pemetrexed plus cisplatin
Preclinical studies
In preclinical testing, the combination of pemetrexed and 
cisplatin showed activity against human non-small cell lung 
cancer cell lines, suggesting potential efﬁ  cacy in MPM. When 
comparing cisplatin or pemetrexed alone versus combination 
treatment in H460 human non-small cell lung carcinoma 
(NSCLC) and Calu-6 NSCLC nude mouse xenografts, a 
greater-than-additive growth delay was noted (Teicher et al 
2000). Pemetrexed was then studied in human patients with 
solid tumors.
Phase I evaluation
In phase I studies, patients with MPM, NSCLC, GI, and 
breast tumors responded to pemetrexed alone (Pearce and 
Alice Miller 2005). In a dose-escalation phase I study of 
patients with various solid tumors, 42 patients were treated 
with pemetrexed and cisplatin on day 1 of a 21-day cycle, 
while 12 patients were treated with pemetrexed on day 1 and 
cisplatin on day 2 of a 21-day cycle (Thodtmann et al 1999). Therapeutics and Clinical Risk Management 2008:4(1) 207
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More toxicity, including 2 deaths from neutropenic sepsis, 
were noted in the split-dosing regimen, so the authors recom-
mended that pemetrexed and cisplatin be administered on the 
same day (Thodtmann et al 1999). Five of 13 patients with 
MPM in this study had a partial response to the combination 
of pemetrexed and cisplatin (Thodtmann et al 1999).
The maximum tolerated dose of pemetrexed 600 mg/m2 
and cisplatin 100 mg/m2, was limited by neutropenia and 
leukopenia.(Eli Lilly and Company 2004a) Transaminitis 
and rash were also noted; pretreatment with glucocorticoids 
reduced the incidence of rash (Adjei et al 2000). Based on 
the results of this trial, pemetrexed 600 mg/m2 and a recom-
mended dose of cisplatin 75 mg/m2 were recommended 
(Eli Lilly and Company, 2004a), and further study of this 
combination in MPM was planned.
Phase II evaluation
A phase II trial of pemetrexed and cisplatin was not con-
ducted in patients with mesothelioma. Based on the Thodt-
mann phase I trial, Shepherd et al (2001) conducted a phase 
II trial of pemetrexed and cisplatin for patients with untreated 
stage IIIB (5/31) or IV (26/31) non-small cell lung cancer. 
Due to toxicity observed in phase I studies, the dose of 
pemetrexed was lowered to 500 mg/ m2. A response rate of 
45% (95% CI 26%–64%) was noted, with a median dura-
tion of response of 6.1 months. The median survival was 8.9 
months (Shepherd et al 2001). Overall, the combination of 
cisplatin and pemetrexed was well tolerated; patients received 
98.0% of the planned dose intensity of cisplatin, and 96.0% 
of the planned dose intensity of pemetrexed (Shepherd et al 
2001). Although one-third of the patients developed grade 
3/4 granulocytopenia, only one case of neutropenic fever 
was recorded (Shepherd et al 2001). Based on these data, 
the same doses of cisplatin and pemetrexed were used in a 
subsequent phase III trial for MPM.
Phase III evaluation
EMPHACIS trial design
After promising results from phase I and II pemetrexed 
trials, a patient-blinded phase III trial (Evaluation of Meso-
thelioma in a Phase III Trial of Pemetrexed with Cisplatin, 
EMPHACIS) randomized 448 chemonaive patients with 
MPM to pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) 
every 21 days versus cisplatin alone (Vogelzang et al 
2003). This was the largest mesothelioma trial to date, and 
these patients were followed for a median of ten months 
(Vogelzang et al 2003). The use of cisplatin alone as a 
control has since been criticized because cisplatin doublets 
were considered to be the standard of care prior to this trial 
(Steele 2003).
While EMPHACIS was underway, Niyikiza et al (2002) 
reported that elevated levels of homocysteine and methylma-
lonic acid, markers of folate and vitamin B12 deﬁ  ciency, were 
associated with increased rates of side effects from peme-
trexed. Patients with both homocysteine and methylmalonic 
acid in the highest quartile were 15.6 times more likely to 
suffer severe toxicity than those with normal levels. Due to 
this analysis, the decision was made mid-trial to administer 
folate and vitamin B12 supplementation to all subsequently 
enrolled patients in an effort to reduce rates of neutropenia 
and leukopenia. At that point, 70 patients had completed the 
trial without receiving vitamin supplementation. Forty-seven 
patients began supplementation partway through the trial, and 
448 patients were subsequently enrolled and received vitamin 
supplements during their entire treatment course. Subsequent 
analysis of the data from this trial was separated by treatment 
arm and also by vitamin supplementation status; however, 
the relatively small number of never supplemented/partially 
supplemented complicates efforts to understand the effect of 
supplementation.
Vitamin supplementation did reduce the toxicity of 
pemetrexed; 52% of unsupplemented/partially supplemented 
patients reported grade 3 or 4 neutropenia, compared to only 
9.4% of fully supplemented patients. Fully supplemented 
patients received a median of 6 cycles of pemetrexed, com-
pared to 2 cycles of treatment for patients who did not receive 
any vitamin supplementation (Vogelzang et al 2003).
EMPHACIS patient characteristics
Due to limited treatment options and poor outcomes in 
MPM, signiﬁ  cant pressure exists to expand the application 
of novel therapies to an ever-broader patient population, but 
overgeneralization increases the risk of poor outcomes. For 
this reason, it is important to examine the characteristics 
of patients included in the EMPHACIS trial. EMPHACIS 
enrolled patients who had unresectable disease or were not 
surgical candidates, who had not received prior chemo-
therapy, and with Karnofsky performance scores   70. Most 
MPM patients are more symptomatic and less functional than 
this at presentation (Green et al 2007), which may limit the 
ability to apply this regimen to other patients.
Twelve percent of patients had received radiation therapy 
prior to enrollment.
Over 80% of patients were male and over 90% Caucasian 
(Vogelzang et al 2003). While 78% of the enrolled patients 
had advanced stage III or IV disease, 85% had epithelial Therapeutics and Clinical Risk Management 2008:4(1) 208
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histology (Vogelzang et al 2003), which has been associated 
with favorable outcome in EPP patient series (Sugarbaker 
et al 1999).
EMPHACIS results
The median survival of patients in the combination arm was 
12.1 months, compared to a median survival of 9.3 months 
in cisplatin-only patients (p = 0.02) (Vogelzang et al 2003). 
Intention-to-treat analysis was not upheld, since eight patient 
data points were absent (Steele and Klabatsa 2005). A 
subgroup analysis of patients who received vitamin supple-
mentation throughout their chemotherapy course showed 
that the median survival of combination-arm patients was 
13.3 months, compared to 10.0 months for cisplatin-only 
patients; however, the difference in median survival in this 
subgroup was no longer statistically signiﬁ  cant (p = 0.051). 
The hazard ratio for death for patients treated with both 
pemetrexed and cisplatin was 0.77. In addition, the median 
time to progression was 5.7 months in the combination arm, 
and 3.9 months for cisplatin alone (p = 0.001). The total 
response rate was 41.3% in the combination arm, and 16.7% 
for cisplatin alone (p   0.0001). No complete responses were 
noted (Vogelzang et al 2003).
In 2005, the ﬁ  nal data from EMPHACIS showed that 
the median survival of patients receiving pemetrexed and 
cisplatin was 12.8 months, compared to 9.0 months for 
those receiving cisplatin alone. Patients receiving combina-
tion therapy had a hazard ratio for death of 0.74 (95% CI 
0.60–0.90, p 0.003) (Vogelzang et al 2005). The US Food 
and Drug Administration (FDA) performed an intention-to-
treat analysis of the EMPHACIS data, and their results also 
favored combination therapy with cisplatin and pemetrexed 
(Hazarika et al 2004).
Patients who achieved an objective response in EMPHA-
CIS had more improvement in pulmonary function tests 
(PFTs) than those with stable disease; in comparison, those 
who progressed on this regimen had a mean decrease in their 
FEV1 and FVC (Paoletti 2003). The differences in FEV1 
and FVC between responders, those with stable disease, 
and those who progressed were all statistically signiﬁ  cant. 
The authors commented that PFTs may be a more sensitive 
indicator of response to this disease, which is difﬁ  cult to 
assess radiographically (Paoletti 2003).
Cisplatin and EMPHACIS
Outcomes in the cisplatin-only arm were unexpectedly poor 
compared to other trials. Although different enrolled popula-
tions make it difﬁ  cult to compare survival rates between two 
clinical trials, concern exists that the low median survival of 
the EMPHACIS cisplatin-only arm may have made combi-
nation therapy appear more effective. The EORTC trial of 
cisplatin 80 mg/m2 with and without raltitrexed 3 mg/m2 did 
not ﬁ  nd a statistically signiﬁ  cant difference between these 
two arms. Reck and Gatzemeier (2005) attribute the differ-
ence in results of EMPHACIS and the EORTC trial to the 
fact that the cisplatin-only arm in EORTC showed a 39.4% 
one-year survival, as opposed to the 17% one-year survival 
in the cisplatin-only arm in EMPHACIS. In addition, the 
EMPHACIS protocol did not specify a goal number of cycles, 
and the fact that control patients received a median of 2 less 
cycles than patients in the combination arm may account 
in part for the difference in survival between the two arms 
(Green et al 2007).
Despite the rosy 23% overall response rate of single-agent 
cisplatin in Berghmans’ meta-analysis (Berghmans et al 
2002). an early phase II trial showed that cisplatin alone led 
to a response rate of only 14.3% and median survival of 7.5 
months in unresectable MPM (Zidar et al 1988). Based on 
these numbers, Budde and Hanna (2004) query the relative 
contribution from cisplatin to the activity of the cisplatin 
plus pemetrexed doublet, going so far as to propose a phase 
III trial of pemetrexed alone.
Post-study chemotherapy after EMPHACIS
The incidence of post-study chemotherapy may have affected 
the survival times of patients in the EMPHACIS study. 
37.6% of patients who received cisplatin and pemetrexed 
and 47.3% of the cisplatin-only patients received a different 
post-study chemotherapy (Vogelzang et al 2003). Patients 
in the cisplatin-only arm were prohibited from receiving 
pemetrexed after the conclusion of the trial. Single-agent 
gemcitabine was the most commonly used post-study 
chemotherapy (PSC).
The median survival of patients treated with cisplatin 
plus pemetrexed and subsequent PSC was 15.3 months 
(95% CI 13.3–18.9 months), compared to median survival 
of 12.2 months (95% CI 9.9–14.2 months) in patients treated 
with cisplatin and pemetrexed without PSC. The median 
survival for combination-arm patients who did not receive 
PSC was 9.8 months (95% CI 8.1–11.7 months), and 6.8 
months (95% CI 6.3–8.7 months) for cisplatin-only patients 
without PSC.
Receiving post-study chemotherapy was associated 
with increased survival (p   0.001) even after adjusting for 
patient prognostic factors and controlling for initial study 
regimen. Due to confounding factors, it is difﬁ  cult to interpret Therapeutics and Clinical Risk Management 2008:4(1) 209
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this survival beneﬁ  t, which may have been due to patients 
with less aggressive disease surviving to receive additional 
chemotherapy, due to either the initial or the subsequent 
chemotherapy regimens, or related to the elapsed interval 
between EMPHACIS regimen and receiving PSC (Manegold 
et al 2005).
Toxicity
When patients enrolled in the phase III EMPHACIS trial were 
supplemented with 350–1000 mg of oral folic acid daily and 
1000 µg of vitamin B12 via intramuscular injection every 
9 weeks, their average homocysteine level fell from 8.3 to 
6.9 µmol/L. In addition, the rate of grade 4 hematologic or 
grade 3/4 nonhematologic toxicity in these supplemented 
patients was 6.4%, compared to 37% in unsupplemented 
patients (Bunn et al 2001). These results show that vitamin 
supplementation lowers homocysteine levels and reduces the 
incidence of toxicity from pemetrexed.
The original maximum tolerated dose of pemetrexed 
was calculated without beneﬁ  t of vitamin supplementa-
tion. In a more recent phase I trial attempting to deﬁ  ne the 
maximum tolerated dose of pemetrexed alone with vitamin 
B12 and folate supplementation, patients were treated with 
up to 800 mg/m2 of pemetrexed with acceptable toxicity 
(Nakagawa et al 2003). It is possible that if additional 
trials were performed with vitamin support, the maximum 
tolerated dose of cisplatin plus pemetrexed might well 
involve even higher doses of pemetrexed (Budde and Hanna 
2004) and perhaps even higher response rates than those 
seen in EMPHACIS.
FDA approval
When independent reviewers and the FDA retrospectively 
assessed the radiographic response data from the phase 
III trial of pemetrexed and cisplatin versus cisplatin alone 
(Vogelzang et al 2003), the FDA only conﬁ  rmed 47 of 94 
partial responses reported by the study authors in the combi-
nation arm. A Cochrane review of pemetrexed and cisplatin 
for the treatment of mesothelioma raised concern that the lack 
of investigator blinding in EMPHACIS may have contributed 
to the discrepancy between trial investigators’ assessment of 
response and that of independent FDA reviewers.
Since the FDA reviewers still noted more responses with 
combination therapy during their reassessment, pemetrexed 
was subsequently approved for the treatment of MPM in the 
United States on 4 February 2004 (Hazarika et al 2005). 
Due to the large number of patients and multiple interna-
tional centers involved in EMPHACIS, the FDA approved 
pemetrexed without requiring a 2nd supporting clinical 
trial demonstrating efﬁ  cacy of cisplatin plus pemetrexed 
(Hazarika et al 2004).
Pemetrexed 500 mg/m2 was approved in combination 
with cisplatin 75 mg/m2 for the treatment of unresectable 
MPM (Hazarika et al 2005). The FDA also recommended 
that patients begin supplementation with folate 350–1000 µg 
daily and vitamin B12 1000 mcg intramuscular every 9 weeks 
3 weeks prior to pemetrexed therapy. In order to reduce the 
incidence of pemetrexed-associated rash, dexamethasone 
pretreatment was recommended on days 0, 1, and 2 of che-
motherapy (Hazarika et al 2005).
Quality of life
With the advent of targeted chemotherapy agents that may 
stabilize tumor growth as opposed to causing clinical regres-
sion, other outcomes measures such as quality of life will be 
more important than ever. In a phase II trial of cisplatin and 
pemetrexed in MPM, 32% of patients showed improvement 
in their Lung Cancer Symptom Scale score (Eli Lilly and 
Company 2004b).
The LCSS-Meso questionnaire has been previously vali-
dated in mesothelioma patients (Hollen et al 2004). LCSS-
Meso was administered to patients in the EMPHACIS trial, 
with a 90% completion rate (Gralla et al 2003). The overall 
symptom score favored the combination arm after 6 cycles 
(p = 0.004) (Boyer et al 2003), and patients in that arm 
received a median of 6 cycles (Vogelzang et al 2003).
By week 12 (4 cycles), a statistically signiﬁ  cant improve-
ment in pain, cough and dyspnea was noted in the pemetrexed 
plus cisplatin arm, compared with the cisplatin-only arm. 
By week 12, similar improvements global quality of life 
(p = 0.025) and fatigue (p = 0.027) favoring the combination 
arm were noted. Anorexia scores favored the combination 
arm by week 18 (p = 0.017) (Gralla et al 2003).
Ongoing/future trials
Based on the results of EMPHACIS, cisplatin and peme-
trexed should be the standard of care (Ellis et al 2006) and 
thus the default comparator for testing the activity of future 
chemotherapy regimens against MPM (Reck and Gatzemeier 
2005). Additional clinical trials are needed to better deﬁ  ne the 
role of cisplatin and pemetrexed in the treatment of MPM, 
including the role of this doublet in combination with radia-
tion therapy or surgical therapy such as pleurectomy/decor-
tication and extrapleural pneumonectomy.
The Extended Access Program (EAP) study will provide 
nonrandomized data about pemetrexed, pemetrexed plus Therapeutics and Clinical Risk Management 2008:4(1) 210
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cisplatin, and pemetrexed plus carboplatin in patients with 
MPM. H3-MCJMEW compares best supportive care with or 
without pemetrexed. SITMP3 treats nonoperative patients 
with cisplatin, and those who do not progress are randomized 
to receive maintenance pemetrexed or pemetrexed at time of 
progression (Favaretto 2005).
Pemetrexed plus carboplatin
Carboplatin is often substituted for cisplatin due to its 
reduced risk of toxicity (Hughes et al 2002). In a phase I 
dose-escalation trial of 27 untreated patients with MPM, 
no dose-limiting toxicities (DLT) were noted in 3 patients 
treated with a combination of pemetrexed 500 mg/m2 and 
carboplatin area-under-the-curve (AUC) 5 mg/mL/minute 
every 21 days. All three of these patients developed at least 
grade 3 leukopenia. Three of 5 patients experienced DLT at 
pemetrexed 500 mg/m2 and carboplatin AUC 6 (2 patients 
with grade 4 neutropenia and 1 with neutropenic sepsis) 
(Hughes et al 2002). In this phase I trial, 8 of 25 assessable 
patients had a partial response (response rate 32%), and 14 
had stable disease (Hughes et al 2002). This response rate 
was higher than prior studies that reported response rates 
between 5 and 16 with single-agent carboplatin (Hughes 
et al 2002).
This phase I trial of carboplatin also reported a median 
survival of 451 days, with a median of 305 days to progres-
sion (Hughes et al 2002). The authors report that 70% of these 
patients described a decrease in “cancer-related symptoms” 
during chemotherapy, but the details of this measurement are 
not described (Hughes et al 2002). The mean GFR of these 
patients was 122 mL/min prior to therapy and 93 mL/minute 
post-treatment (p   0.001), but the authors felt this decrease 
was not clinically signiﬁ  cant (Hughes et al 2002).
A subsequent Italian phase II trial treated 102 patients 
with MPM with pemetrexed 500 mg/m2 and carboplatin 
area-under-the-curve (AUC) 5 mg/mL/minute every 21 
days for a median of 6 cycles. All patients received vitamin 
B12 and folate supplementation. Two patients had complete 
responses, and 17 had a partial response, for a total response 
rate of 18.6% (95% CI 11.6%–27.5%) (Ceresoli et al 2006), 
which was markedly lower than the 32% noted in the Hughes 
phase I study.
In the Ceresoli trial, 47% (95% CI 37.1%–57.2%) had 
stable disease. The median survival was 12.7 months, with 
median time to progression of 6.5 months. 19.6% of patients 
developed Grade 3-4 neutropenia, and 11.7% experienced 
grade 3-4 anemia (Ceresoli et al 2006). Overall, the treat-
ment was very well tolerated; of the 96 patients receiving 
over 2 cycles of pemetrexed and carboplatin, relative dose 
intensity was 97% for pemetrexed and 98% for carboplatin 
(Ceresoli et al 2006).
To date, there have been no published phase III data 
examining the efﬁ  cacy of pemetrexed and carboplatin in the 
treatment of MPM.
Conclusion
The worldwide incidence of malignant pleural mesothelioma 
continues to rise, but treatment options have historically been 
limited. Surgical resection is technically difﬁ  cult and quite 
morbid, and standard doublet chemotherapy has not been par-
ticularly effective. In recent years, the promising combination 
of pemetrexed plus cisplatin has been developed and tested 
in the treatment of MPM. The large phase III EMPHACIS 
trial showed improved outcomes in patients treated with both 
cisplatin and pemetrexed versus cisplatin alone. Ongoing and 
future testing will likely expand the role of this regimen in 
this disease. Combining cisplatin plus pemetrexed and other 
treatment modalities such as radiotherapy, surgical resec-
tion or targeted molecular therapies may lead to improved 
patient outcomes.
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